What is it about?
The prevalence of obesity is increasing globally, and there is a need to monitor the effects of drug dosage from a pre- to post-gastric bypass scenario. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole.
Photo by Simone van der Koelen on Unsplash
Why is it important?
Clinical bioavailability trial that evaluates whether Roux-en-Y gastric bypass (RYGB) modifies the pharmacokinetics of Omeprazole. Our study analyzes the absorption changes (pre- post surgery) in this special population, as well as compares pharmacokinetics after surgery vs matched controls. This knowledge is relevant given the highly prevalent use of omeprazole in this population.
Read the Original
This page is a summary of: EFFECT OF OBESITY AND ROUX-EN-Y GASTRIC SURGERY ON OMEPRAZOLE PHARMACOKINETICS, Obesity Facts, January 2022, Karger Publishers, DOI: 10.1159/000521570.
You can read the full text:
The following have contributed to this page